{"id":"NCT01669811","sponsor":"AstraZeneca","briefTitle":"Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)","officialTitle":"A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of D961H 20 mg Twice Daily Oral Administration and D961H 20 mg Once Daily Oral Administration in Patients With Refractory Reflux Esophagitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08","primaryCompletion":"2014-05","completion":"2014-05","firstPosted":"2012-08-21","resultsPosted":"2015-08-14","lastUpdate":"2015-08-27"},"enrollment":1398,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Refractory Reflux Esophagitis"],"interventions":[{"type":"DRUG","name":"Esomeprazole (D961H) twice daily","otherNames":[]},{"type":"DRUG","name":"Esomeprazole (D961H) once daily","otherNames":[]}],"arms":[{"label":"D961H 20mg twice daily","type":"EXPERIMENTAL"},{"label":"D961H 20mg once daily","type":"ACTIVE_COMPARATOR"}],"summary":"This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of esomeprazole magnesium salt) with refractory reflux esophagitis after 8 weeks of standard Proton-pump inhibitor (PPI) therapy by assessment of presence/absence of inflammation (esophagitis) at Week 8 according to the Los Angeles (LA) classification","primaryOutcome":{"measure":"Percentage of Participants With Healing of RE Who Were Graded \"O\" at Week 8 Out of Participants Who Were Graded \"A\" to \"D\" at Baseline According to Los Angeles Classification","timeFrame":"8 Weeks","effectByArm":[{"arm":"D961H 20mg Bid","deltaMin":92.4,"sd":null},{"arm":"D961H 20mg QD + Placebo","deltaMin":68.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":63,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=712&filename=D961UC00002_Synopsis.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":145},"commonTop":["Nasopharyngitis"]}}